Topotecan in Pretreated Metastatic Neuroendocrine Carcinoma

#974

Introduction: Therapeutic options for metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy are limited. Topotecan is an approved second line chemotherapy for small cell lung cancer (SCLC). NEC is often considered to show a biological behavior similar to SCLC.

Aim(s): To analyze the efficacy of topotecan in pretreated metastastic NEC patients.

Materials and methods: We performed a retrospective analysis of all patients treated with topotecan for metastastic NEC at our center between April 2008 and July 2013 (n=16).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Apostolidis L

Authors: Apostolidis L, Jäger D, Winkler E,

Keywords: neuroendocrine carcinoma, chemotherapy, topotecan,